Relapse prevention and recovery in the treatment of schizophrenia

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 5, 2006, Pages 19-23

  Schooler, Nina R ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ANHEDONIA; BLUNTED AFFECT; COGNITIVE THERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH EDUCATION; HUMAN; LONG TERM CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RECURRENCE RISK; RELAPSE; REMISSION; REVIEW; SCHIZOPHRENIA; SOCIAL ADAPTATION; SOCIAL INTERACTION; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; BEHAVIOR THERAPY; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT EDUCATION; PROFESSIONAL-FAMILY RELATIONS; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; RECURRENCE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 33744787362     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Tardive dyskinesia: summary of a task force report of the American Psychiatric Association by the Task Force on Late Neurological Effects of Antipsychotic Drugs. Am J Psychiatry 1980;137:1163-1172
2. Hogarty GE, Ulrich RF. Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry 1977;34:297-301
3. Schooler NR, Levine J, Severe JB, et al. Prevention of relapse in schizophrenia: an evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980;37:16-24
4. Hogarty GW, Schooler NR, Ulrich R, et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 1979;36:1283-1294
5. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
6. Kujawa MJ, Saha AR, Ingenito GG, et al. Aripiprazole for long-term maintenance treatment in schizophrenia. In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, Pa. Abstract NR376:102
7. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
8. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441-449
9. Robinson DG, Woerner MG, McMeniman M, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:473-479
10. Liberman RP. Psychosocial treatments for schizophrenia. Psychiatry 1994;57:104-114
11. Pharoah FM, Rathbone J, Mari JJ, et al. Family intervention for schizophrenia. Cochrane Database Syst Rev 2003;(4):CD000088
12. Bellack AS, Schooler NR, Marder SR, et al. Do clozapine and risperidone affect social compliance and problem solving? Am J Psychiatry 2004;161:364-368
13. Marder SR, Wirshing WC, Mintz J, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry 1996;153:1585-1592
14. Turkington D, Kingdon D, Weiden PJ. Cognitive behavior therapy for schizophrenia. Am J Psychiatry 2006;163:365-373
15. Tamer N, Yusupoff L, Kinney C, et al. Randomised controlled trial of intensive cognitive behavior therapy for patients with chronic schizophrenia. BMJ 1998;317:303-307
16. Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-behavioral therapy intervention in the treatment of schizophrenia. Br J Psychiatry 2002;180:523-527